22VAH837: Novel Targeting of the Microenvironment to Decrease Metastatic Recurrence of High-Risk TNBC: A Randomized Phase II Study of Tetrathiomolybdate (TM) Plus Capecitabine in Patients with Breast Cancer at High Risk of Recurrence
Principal Investigator
Study Number
STUDY02001837
Summary
This study is for patients with triple negative breast cancer (TNBC) with a moderate or high risk of cancer recurrence. The study is divided into two parts. In Phase 1b, all participants will receive tetrathiomolybdate (TM), capecitabine, and pembrolizumab. In Phase 2, participants will be randomly assigned to receive either TM with capecitabine or capecitabine alone. Participants will have an equal chance of being assigned to each treatment. Capecitabine and pembrolizumab are FDA-approved treatments for TNBC. TM is a pill that lowers the amount of copper in the blood. TM is not approved by the FDA to treat cancer patients and is investigational in this study. The purpose of this study is to learn whether decreasing the amount of copper in the blood can help prevent breast cancer from coming back in patients with this type of cancer.
Phase
I/II
Contact
Available at the following location(s)
- Lebanon
View more details at ClinicalTrials.gov
Do you need help with some of the labels on this page?
Read our glossary of terms